Travere Therapeutics, Inc. filings document a rare-disease biopharmaceutical issuer whose disclosures center on FILSPARI (sparsentan), operating results, FDA regulatory events, and public-company governance. Recent 8-K reports furnish quarterly and annual financial results and disclose regulatory events involving FILSPARI in focal segmental glomerulosclerosis and IgA nephropathy.
Proxy materials cover annual meeting voting, board matters, executive compensation, equity awards, and stockholder governance. The filing record also documents formal event reporting under the Exchange Act for product-regulatory updates and financial-condition disclosures.
Travere Therapeutics, Inc. officer Christopher Cline gave notice of a proposed sale of 1,014 common shares, with an aggregate market value of $43,206.54 and an approximate sale date of April 15, 2026. Cline acquired the 1,014 shares from the issuer as performance shares on April 13, 2026. The notice identifies a Rule 10b5-1 plan adopted May 28, 2025.
Travere Therapeutics, Inc. (TVTX) officer Jula Inrig reported a proposed sale of 1,018 common shares, with an aggregate market value of $43,376.98 and an approximate sale date of April 15, 2026. The shares were acquired from the issuer as performance shares on April 13, 2026.
Travere Therapeutics, Inc. officer Elizabeth E. Reed reported that 7,215 common shares are to be sold, with an aggregate market value of $302,515.98 and an approximate sale date of April 14, 2026. She acquired 7,215 shares through performance restricted stock unit vesting on April 13, 2026. Reed said the sale is mandated by the issuer’s election under its equity incentive plans to cover tax withholding through a “sell to cover” transaction with the designated broker, Morgan Stanley Smith Barney; she said it is not discretionary. The three-month sales table separately lists 37,500 common shares sold on April 14, 2026, for gross proceeds of $1,540,125.00.
Travere Therapeutics, Inc. officer Jula Inrig gave notice of a proposed sale of 7,215 common shares, with an approximate sale date of April 14, 2026 and an aggregate market value of $302,515.98. Morgan Stanley Smith Barney is named as the broker.
The shares were acquired through performance restricted stock unit vesting on April 13, 2026. The remarks say the sale is required under the issuer’s equity incentive plans to fund tax withholding through a brokerage firm designated by the issuer, and is not discretionary. Elizabeth E. Reed signed as attorney-in-fact for Inrig.
Travere Therapeutics, Inc. (TVTX) officer Peter Heerma reported a proposed sale of 7,215 common shares, with an approximate sale date of April 14, 2026 and an aggregate market value of $302,515.98.
The shares were acquired through performance restricted stock unit vesting on April 13, 2026, as compensation. The remarks state that the sale is mandated by Travere's equity incentive plans to cover tax withholding through a brokerage firm designated by the issuer, and is not discretionary. The form also reports that Peter Heerma sold 7,310 shares on February 3, 2026, for gross proceeds of $234,799.04.
Travere Therapeutics, Inc. (TVTX) lists a proposed sale by Officer Christopher Cline of 7,239 common shares, with an aggregate market value of $303,522.27, on approximately April 14, 2026.
Cline acquired the shares from the issuer on April 13, 2026, through performance restricted stock unit vesting as compensation. The sale is a mandatory “sell to cover” transaction under the issuer’s election under its equity incentive plans to fund tax withholding; the remarks state that it is not discretionary. Travere reported 92,241,550 common shares outstanding.
Travere Therapeutics, Inc. (TVTX) officer Christopher Cline reported a proposed sale of 9 common shares, with an aggregate market value of $369.63 and an approximate sale date of April 14, 2026. Cline acquired 9 shares of restricted stock from the issuer on April 10, 2026. The listed Rule 10b5-1 plan adoption or instruction date is May 28, 2025.
During the past three months, Cline reported sales of 65 shares on April 13, 2026, for gross proceeds of $1,875.25; 1,745 shares on February 4, 2026, for $56,165.62; and 7,242 shares on February 3, 2026, for $232,616.03.
TVTX submitted a Form 144 notice proposing the sale of 37,500 shares of Common Stock related to a stock option exercise, with the proposed sale dated 04/14/2026 and cash proceeds indicated. The filing also lists multiple recent open-market dispositions by Elizabeth Reed, each showing trade dates, share counts, and gross proceeds.
TVTX submitted a Form 144 notice reporting the proposed sale of 32,750 common shares via a stock option exercise on 04/14/2026, with cash as the payment method. The filing also records a prior sale of 10,000 common shares by Roy Baynes on 04/06/2026 for $330,000.